Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

This trial (called SAPHIRE) is testing whether adding a drug called sapanisertib to the standard treatment cabozantinib improves outcomes for people with advanced liver cancer (hepatocellular carcinoma or HCC) that has a specific genetic mutation in a protein called beta-catenin. **You may be eligible if...** - You have confirmed liver cancer (HCC) that cannot be cured with surgery or local treatments - Your tumor has a beta-catenin (CTNNB1) gene mutation, confirmed by genetic testing - You have already received at least one prior systemic (whole-body) cancer treatment - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - Your tumor does not have a beta-catenin mutation - You have not yet received any prior cancer treatment - Your liver or other organ function is too impaired - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.